Overview

Detailed Summary

Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA.
The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix.
Syschem has materially increased production volumes year-on-year (1,269 MT to 1,780 MT) and reported quarterly ramp to 820 MT in Q3 FY25-26, indicating improving capacity utilization ahead of announced expansion; management explicitly states a strategic focus on increasing year-on-year production to capture rising API demand and export opportunities.
Exports are accelerating: export sales increased to ₹107.62 crore in 9M FY25-26 versus ₹90.89 crore in FY24-25, with Q3 exports doubling year-on-year, indicating successful market traction overseas and the potential to diversify revenue as domestic volumes also expand across 12 Indian states and multiple international markets.
The board emphasizes reliable supply, world-class quality and continuous innovation as core strategic pillars; with an experienced promoter-led management team and a growing client list of domestic formulators, Syschem positions itself as a mid-sized, quality-focused API supplier pursuing scale and regulatory alignment to win larger institutional customers.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 171 Cr
Volatility: Moderate Risk
P/E Ratio: 27.8
Industry P/E: 37.7
PEG Ratio: 0.2
P/B Ratio: 1.2
52W High: 61.00
52W Low: 29.29

Sales CAGR

1Y: 65.42%
3Y: 80.54%
5Y: 34.42%
10Y: 67.52%

Profit CAGR

1Y: -83.33%
3Y: —
5Y: —
10Y: —

ROE

TTM

‌

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
BROOKS		63.00	188 Cr	14.26	1.54	0.00	20.04	19.30	8.92
PAR		134.37	174 Cr	12.01	1.55	0.00	11.71	15.56	11.21
SYSCHEM		31.50	171 Cr	27.79	1.19	0.00	8.93	13.60	2.10
ACHYUT		6.90	164 Cr	513.63	4.69	0.00	0.90	1.13	0.84
CURIS		218.65	161 Cr	29.98	4.29	0.00	0.00	0.00	0.00
AUROLAB		259.00	160 Cr	34.12	3.72	0.00	4.47	7.31	1.55
GUJINJEC		10.26	156 Cr	51.86	13.14	0.00	15.34	21.17	8.18
Median: 7 Co.	—	63.00	164 Cr	29.98	3.72	0.00	8.93	13.60	2.10

Standalone Quarterly Results (in ₹ Crores)

Total

QoQ

YoY

Total

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	75	88	48	78	119	109	104	142	219	109
Expenses	73	87	47	77	117	107	100	136	210	109
Operating Profit	1.62	0.81	0.07	1.20	1.90	2.47	3.30	5.96	9.37	0.55
OPM %	2.17	0.93	0.15	1.54	1.60	2.26	3.19	4.21	4.27	0.50
Other Income	0.15	0.01	0.00	0.02	0.02	0.01	0.01	0.00	0.00	0.05
Interest	0.01	0.00	0.03	0.04	0.00	0.04	0.01	0.17	2.04	0.49
Depreciation	0.67	0.68	0.68	0.68	0.91	0.76	0.76	0.82	1.73	1.56
Profit Before Tax	1.09	0.14	-0.64	0.50	1.01	1.67	2.55	4.97	5.60	-1.45
Tax %	123.85	0.00	0.00	0.00	54.46	0.00	25.49	15.90	68.93	-15.17
Net Profit	-0.26	0.14	-0.64	0.50	0.46	1.67	1.90	4.17	1.74	-1.67
EPS in Rs	-0.05	0.02	-0.12	0.10	0.09	0.31	0.28	0.60	0.28	-0.28

Standalone Profit Loss (in ₹ Crores)

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	3.72	14	77	110	88	74	66	130	233	386	574
Expenses	4.53	13	63	90	77	80	65	122	226	382	554
Operating Profit	-0.81	0.95	13	20	11	-5.16	0.57	8.65	6.98	3.98	19
OPM %	-21.84	7.03	17.10	18.31	12.46	-6.93	0.86	6.63	2.99	1.03	3.34
Other Income	0.01	0.00	-0.18	0.08	0.09	0.26	0.13	0.25	0.17	0.04	0.06
Interest	0.01	0.03	0.15	0.01	0.02	0.06	0.28	0.04	0.25	0.07	2.71
Depreciation	2.16	2.05	2.08	2.15	2.15	2.35	2.58	2.70	2.79	2.95	4.87
Profit Before Tax	-3.05	-2.14	0.60	1.50	-2.20	-7.31	-2.17	6.15	4.11	1.01	12
Tax %	26.59	30.50	43.92	49.94	15.78	23.91	21.44	26.62	32.86	54.52	47.30
Net Profit	-2.24	-1.49	0.34	0.75	-1.85	-5.57	-1.71	4.51	2.76	0.46	6.14
EPS in Rs	-0.33	-0.31	0.11	0.13	-0.35	-1.04	-0.32	0.87	0.52	0.09	0.88
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	16	16	16	19	19	22	23	32	40	44
Reserves	-8.15	-8.64	-7.14	-6.77	-8.78	-14	-16	-9.59	17	48
Borrowings	27	20	19	15	16	15	1.75	1.61	0.45	0.00
Other Liabilities	12	17	29	35	36	55	51	69	107	126
Total Liabilities	47	44	58	62	62	77	60	93	164	217
Fixed Assets	32	29	29	27	28	30	32	31	31	53
CWIP	0.61	0.90	0.31	0.01	0.66	0.98	0.00	0.15	4.11	0.29
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	15	14	28	35	34	46	28	62	129	164
Total Assets	47	44	58	62	62	77	60	93	164	217

Standalone Cash Flows (in ₹ Crores)

Total

YoY

Total

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.47	6.38	0.01	-1.71	3.46	3.72	1.07	-8.49	-26	-10
Cash from Investing Activity	0.09	0.35	0.29	1.83	-3.62	-3.77	-0.78	-1.65	-6.46	-22
Cash from Financing Activity	-0.54	-6.80	-0.15	-0.01	-0.02	-0.06	-0.28	11	32	34
Net Cash Flow	0.02	-0.07	0.14	0.11	-0.18	-0.11	0.00	0.54	-0.48	2.04

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Apr 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026
Promoters	53.89%	53.89%	53.17%	53.17%	57.02%	57.02%	56.71%	56.71%	56.71%	60.86%	60.15%	63.38%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.25%	0.25%	0.20%	0.20%	0.18%	0.18%	0.18%	0.18%	0.18%	0.16%	0.16%	0.15%
Public	45.86%	45.86%	46.63%	46.63%	42.80%	42.80%	43.11%	43.11%	43.11%	38.97%	39.69%	36.47%
Total Shareholders	13,942	13,310	13,305	13,445	13,223	13,223	12,906	13,273	12,836	12,901	12,809	12,825

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Investor Presentation

Q1 FY27

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q4 FY23

Investor Presentation

Q2 FY23

Investor Presentation

Q1 FY23

‌
‌

AGM/EGM Notice

5 days ago

Syschem: Newspaper Notice for 33rd AGM

Syschem (India) Ltd published newspaper advertisements informing shareholders of the dispatch of the Notice for the 33rd Annual General Meeting to be held through VC/AVM; notice and report available on company website.

Frequently Asked Questions about Syschem (India) Ltd

Syschem (India) Ltd (SYSCHEM) is currently trading at 31.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA. The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix. Syschem has materially increased production volumes year-on-year (1,269 MT to 1,780 MT) and reported quarterly ramp to 820 MT in Q3 FY25-26, indicating improving capacity utilization ahead of announced expansion; management explicitly states a strategic focus on increasing year-on-year production to capture rising API demand and export opportunities. Exports are accelerating: export sales increased to ₹107.62 crore in 9M FY25-26 versus ₹90.89 crore in FY24-25, with Q3 exports doubling year-on-year, indicating successful market traction overseas and the potential to diversify revenue as domestic volumes also expand across 12 Indian states and multiple international markets. The board emphasizes reliable supply, world-class quality and continuous innovation as core strategic pillars; with an experienced promoter-led management team and a growing client list of domestic formulators, Syschem positions itself as a mid-sized, quality-focused API supplier pursuing scale and regulatory alignment to win larger institutional customers.

Over the past 52 weeks, Syschem (India) Ltd has traded between a low of ₹29.29 and a high of ₹61.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Syschem (India) Ltd has a market capitalization of approximately 170.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Syschem (India) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 170.66 Cr, Syschem (India) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Syschem (India) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Syschem (India) Ltd is 27.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Syschem India Ltd

Investor's Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Syschem India Ltd

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements